<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03043053</url>
  </required_header>
  <id_info>
    <org_study_id>2016P002810</org_study_id>
    <nct_id>NCT03043053</nct_id>
  </id_info>
  <brief_title>The Effects of Oxytocin in Obese Adults</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Repeat Doses of Intranasal Oxytocin in Obese Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double blind, placebo-controlled study of the effects of intranasal
      oxytocin in obese adults, ages 18-45 years old. Subjects will be randomized to receive of
      intranasal oxytocin or placebo (3 sprays per nostril, 4 times per day) for 8 weeks. Study
      visits include screening to determine eligibility, a 2-part baseline visit, and visits every
      2 weeks thereafter until week 14, with a safety follow-up visit 6 weeks after the last dose
      of study drug. Study procedures include behavioral, metabolic, neuroimaging, and endocrine
      assessments.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean difference in weight loss between Oxytocin and placebo 8 weeks after Baseline</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>The difference between the mean weight loss values between Oxytocin and placebo-treated groups at 8 weeks after Baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in resting energy expenditure after 8 weeks of Oxytocin versus placebo</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Change in resting energy expenditure from Baseline to 8 weeks in the oxytocin versus placebo-treated groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fat depots after 8 weeks of Oxytocin versus placebo</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Change in fat depots from baseline to 8 weeks in the Oxytocin versus placebo-treated groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in caloric intake after 8 weeks of Oxytocin versus placebo</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Difference in caloric intake after 8 weeks of Oxytocin versus placebo treatment, mediated by change in fMRI activatio of reward-related food motivation brain areas and impulse control</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oxytocin nasal spray (24 IU nasal spray, 4 times per day for 8 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo nasal spray (4 times per day for 8 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxytocin nasal spray</intervention_name>
    <description>oxytocin intranasal spray</description>
    <arm_group_label>oxytocin</arm_group_label>
    <other_name>Syntocinon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo nasal spray</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-45 years old;

          -  BMI 30-45 kg/m2

        Exclusion Criteria:

          -  Use of drug affecting metabolism, glucose, or appetite;

          -  history of medication changes within 4 weeks of enrollment;

          -  active substance use;

          -  history of cardiovascular disease, gastrointestinal disorders, bariatric surgery,
             epilepsy, untreated thyroid disease;

          -  hematocrit &gt;2% below normal;

          -  fasting glucose &gt; 125 mg/dL or hemoglobin A1c â‰¥ 6.5% ;

          -  ALT or AST &gt;2.5 times upper limit of normal;

          -  Cr &gt;1.5 mg/dL; hyponatremia;

          -  pregnancy or breastfeeding;

          -  unwilling to use medically acceptable form of contraception (females only)

          -  follows a nonstandard diet (e.g., gluten free, pescatarian, vegetarian, vegan, Paleo,
             Atkins, raw diet, macrobiotic diet)

          -  current smoking or tobacco use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth A Lawson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisa Asanza, MSN, MPH</last_name>
    <phone>617-726-9394</phone>
    <email>easanza@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisa Asanza, NP</last_name>
      <phone>617-726-9394</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2017</study_first_submitted>
  <study_first_submitted_qc>February 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2017</study_first_posted>
  <last_update_submitted>February 7, 2018</last_update_submitted>
  <last_update_submitted_qc>February 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Elizabeth Austen Lawson</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine, Harvard Medical School</investigator_title>
  </responsible_party>
  <keyword>weight loss</keyword>
  <keyword>body mass index</keyword>
  <keyword>oxytocin</keyword>
  <keyword>magnetic resonance imaging</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

